MichaelAndreeffMDPhD

Hematology • Houston, TX

Hematologic Oncology

Professor of Medicine, Haas Chair in Genetics, Chief, Molecular Hematology and Therapy, U.T. MD Anderson Cancer Center

Join to view full profile

Dr. Andreeff is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Andreeff's full profile

Already have an account?

Office
1515 Holcombe Blvd
Houston, TX 77030
Phone+1 713-792-6161

Summary

Dr. Michael Andreeff is a Houston-based specialist in Hematology with a subspecialty in Hematologic Oncology. He completed his medical degree at the University of Heidelberg Faculty of Medicine in 1968 and earned his Ph.D. in Cell Biology from the University of Heidelberg Medical School. His areas of expertise include hematologic oncology, myelodysplasia, and Acute Myeloid Leukemias. He has been a pioneer in Flow Cytometry and has developed numerous agents which are now in Leukemia therapy, including G-CSF, Sorafenib, Venetoclax, MDM2- and IAP- and menin-inhibitors, as well first-in-class MYC/GSPT1 degraders.. Dr. Andreeff has authored >800 publications, including pre-clinical and clinical studies on the therapy of myeloid and lymphoid leukemias. He also developed a pioneering technology for the therapy of solid tumors involving gene-modified mesenchymal stem cells, that convert immunologically "cold" into "hot" tumors.

Education & Training

University of Heidelberg Medical SchoolPh.D., Cell Biology, 1971 - 1976
University of Heidelberg Faculty of MedicineClass of 1968

Certifications & Licensure

FL State Medical License 2021 - Present
TX State Medical License 1991 - 2025

Clinical Trials

IUdR/BUdR Cell Cycle Labelling Start of enrollment: 1992 May 01
Completed
Not Applicable
2-Chlorodeoxyadenosine and Cytarabine in Patients With Idiopathic Hypereosinophilic Syndrome (HES) Start of enrollment: 1998 Mar 01
Completed
Phase 2
Granulocyte-colony Stimulating Factor (G-CSF) and Plerixafor Plus Sorafenib for Acute Myelogenous Leukemia (AML) With FLT3 Mutations Start of enrollment: 2010 Oct 29
Completed
Phase 1

Publications & Presentations

PubMed

Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia.
Courtney D DiNardo, Wei-Ying Jen, Koichi Takahashi, Tapan M Kadia, Sanam Loghavi
Leukemia. 2025-02-25
A phase II trial of azacitidine with ipilimumab, nivolumab, or ipilimumab and nivolumab in previously untreated myelodysplastic syndrome.
Ian M Bouligny, Guillermo Montalban-Bravo, Koji Sasaki, Naval Daver, Elias Jabbour
Haematologica. 2025-02-20
BKT300: A Novel Anti-Leukemic Small Molecule Targeting the Protein Regulator of Cytokinesis 1 (PRC1) Pathway.
Amnon Peled, Michal Abraham, Hanna Wald, Ophir Hay, Shira Hagbi
Research Square. 2025-02-19

Journal Articles

Integrative Genomic Analysis of Adult Mixed Phenotype Acute Leukemia Delineates Lineage Associated Molecular Subtypes
Koichi Takahashi, Marina Konopleva, Steven Kornblau, Hagop Kantarjian, Nitin Jain, Elias Jabbour, Courtney D DiNardo, Michael Andreeff, Nature
NSG-S Mice for Acute Myeloid Leukemia, Yes. For Myelodysplastic Syndrome, No
Michael Andreeff, MD, Haematologica
PTEN Status Is a Crucial Determinant of the Functional Outcome of Combined MEK and mTOR Inhibition in Cancer
Michael Andreeff, Marina Konopleva, Nature

Abstracts/Posters

Inhibition of Mcl-1 Enhances the Efficacy of Tyrosine Kinase Inhibition in FLT3 Mutated AML and Synergizes with Venetoclax Targeting AML Stem Cells
Michael Andreeff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
AXL/Mertk Inhibitor ONO-7475 Potently Synergizes with BCL2 Inhibitor ABT-199, Overcomes ABT-199 Resistance Mechanisms, and Kills FLT3 ITD AML Cells
Michael Andreeff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Synergistic Targeting of BTK and E-Selectin/CXCR4 in the Microenvironment of Mantle Cell Lymphomas
Michael Andreeff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Dual Targeting of Mitochondrial Unfolded Protein Response and BCL2 in Acute Myeloid Leukemia
Michael Andreeff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Determinants of Outcomes of FLT3mut Acute Myeloid Leukemia with First Salvage Therapy
Michael Andreeff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Oxphos Inhibition Induces Formation of Tunneling Nanotubes in AML Cells and Facilitates Mitochondrial Transfer from BM Stroma to AML That Contributes to Microenvironme...
Michael Andreeff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Genomic Context and TP53 Allele Frequency Define Prognostic Subgroups and Response Outcomes in TP53 Mutated Myelodysplastic Syndromes
Michael Andreeff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Cage Transcriptome Analysis Reveals BCL2A1 Upregulation in FLT3-ITD/D835 Dual Mutated AML Cells Harboring Complex Co-Mutations
Michael Andreeff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Patients with Acute Myeloid Leukemia (AML) ...
Michael Andreeff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Impact of p53 Knock-Down on T-Cell Proliferation and T-Cell Mediated Cytotoxicity Against AML Cell Lines Mediated By a CD33 Specific BiTE¬ Antibody Construct
Michael Andreeff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Outcomes of Relapsed or Refractory Acute Myeloid Leukemia after Frontline Hypomethylating Agent with Venetoclax Regimens
Michael Andreeff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Dual Inhibition of MDM2 and XPO1 Synergizes to Induce Apoptosis in Acute Myeloid Leukemia Progenitor Cells with Wild-Type TP53 through Nuclear Accumulation of p53 and ...
Michael Andreeff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Inhibition of Anti-Apoptotic Mcl-1 Exerts Anti-Leukemia Activity through Modulation of Leukemia-Stromal Interactions and Metabolic Functions in AML
Michael Andreeff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Single-Cell Mapping of Stress Response and Cell Death Pathways in Acute Myeloid Leukemia Reveals Stressor-Specific Alterations and Distinct Response Patterns
Michael Andreeff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Outcomes in Molecular Subgroups and Resistance Patterns with Ten-Day Decitabine and Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia
Michael Andreeff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
TP73 As Novel Determinant of Resistance to BCL-2 Inhibition in Acute Myeloid Leukemia
Michael Andreeff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Identification of Gene Expression Signatures in Leukemia Stem Cells and Minimal Residual Disease Following Treatment of Adverse Risk Acute Myeloid Leukemia
Michael Andreeff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Updated Preliminary Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome
Michael Andreeff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
CG-806, a First-in-Class Pan-FLT3/Pan-BTK Inhibitor, Exhibits Broad Signaling Inhibition in Chronic Lymphocytic Leukemia Cells
Michael Andreeff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Dose Escalation Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
Michael Andreeff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
TP53 Deficient/Mutant AMLs Are Resistant to Individual BH3 Mimetics: High Efficacy of Combined Inhibition of Bcl-2 and Mcl-1
Michael Andreeff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Results of a Phase II TrialClinically Relevant Abstract
Michael Andreeff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
p53 Mediated Bone Marrow Mesenchymal Stem Cell Expansion Supports Acute Myeloid Leukemia Development
Michael Andreeff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Intravital Imaging of Bright Cyan-Fluorescent AML Model Reveals Impact of CXCR4 Inhibitor on AML and Immune Cell Dynamics
Michael Andreeff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Incidence of Serious Adverse Events, Pneumonitis, Infection and Sepsis in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphom...
Michael Andreeff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all

Lectures

A Phase 1 Dose Escalation Study of Milademetan in Combination with 5-Azacitidine (AZA) in Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndr...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Targeting Misfolded p53 and p53 Aggregation to Overcome Resistance to Apoptosis in Acute Myeloid Leukemia
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Diverse Landscape of TET2 Variants in MDS and AML
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Final Results of Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Acute Myeloid Leukemia Expands Osteoprogenitor Rich Niche in the Bone Marrow but Resorbs Mature Bone Causing Osteopenia/Osteoporosis in Animal Models
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Single-Cell Atlas of Driver Mutations in Acute Myeloid Leukemia (AML)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Targeting Wnt/β-Catenin and BCL-2, Two Critical Survival Factors, Synergistically Induces Apoptosis in AML Via Rac1-Mediated MCL-1 Inhibition
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Join now to see all

Authored Content

A Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (Pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML)October 2017
MCL-1 up-Regulation Through MAPK Activation Confers Acquired Resistance to BCL-2 Inhibitor ABT-199 in Pre-Clinical AML ModelsOctober 2017
The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II TrialOctober 2017

Press Mentions

New Findings Show Moleculin's Annamycin Overcomes Resistance to Venetoclax in AMLNovember 18th, 2024
MD Anderson Research Highlights for February 22, 2023February 22nd, 2023
Is Leukemia Truly Incurable and Fatal?January 14th, 2023
Join now to see all

Grant Support

Ph1/2 Study of the Imipridone ONC201 for Treatment of AML IND125,203 (12/23/2014)UNIVERSITY OF TX MD ANDERSON CAN CTR2019–2027
Ph1/2 Study of the Imipridone ONC201 for Treatment of AML IND125,203 (12/23/2014)UNIVERSITY OF TX MD ANDERSON CAN CTR2019–2027
Ph1/2 Study of the Imipridone ONC201 for Treatment of AML IND125,203 (12/23/2014)UNIVERSITY OF TX MD ANDERSON CAN CTR2019–2027
Therapeutic targeting of p53 reactivation-induced OXPHOS dependency and stress responses to overcome resistance to venetoclax/HMA in AMLUNIVERSITY OF TX MD ANDERSON CAN CTR2022–2024